Literature DB >> 21451492

Targeted therapies: dasatinib sensitizes KRAS-mutant colorectal cancer tumors to cetuximab.

Lisa Hutchinson.   

Abstract

Entities:  

Year:  2011        PMID： 21451492     DOI： 10.1038/nrclinonc.2011.24

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.

Authors:  E F Dunn; M Iida; R A Myers; D A Campbell; K A Hintz; E A Armstrong; C Li; D L Wheeler
Journal:  Oncogene       Date:  2010-10-18       Impact factor: 9.867
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.